|
Jul 28
|
This Could Send Ozempic's Sales Potential to a Whole Other Level
|
|
Jul 27
|
Novo Nordisk's Next-Gen Diabetes Candidate Could Challenge Ozempic -- Is the Stock a Buy?
|
|
Jul 26
|
June PCE inflation print, auto earnings: Morning Brief
|
|
Jul 26
|
EMA backs Wegovy cardiovascular label update as Novo seeks EU coverage
|
|
Jul 26
|
Is Eli Lilly's Stock in a Bubble?
|
|
Jul 26
|
EU approves Novo Nordisk's Wegovy for heart, stroke treatment
|
|
Jul 26
|
Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?
|
|
Jul 25
|
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
|
|
Jul 25
|
Viking Therapeutics Unveils Monthly Weight-Loss Shot, Rocking Eli Lilly, Novo Nordisk
|
|
Jul 25
|
Why Viking’s Weight-Loss Drug News Is Weighing on Eli Lilly, Novo Nordisk Stocks
|
|
Jul 25
|
European regulatory authority adopts a positive opinion for an update of the Wegovy® label to reflect risk reduction of major adverse cardiovascular events
|
|
Jun 19
|
June 2024 Insights Into Three Stocks Estimated As Undervalued
|
|
Jun 18
|
Why the GLP-1 impact on other industries 'will take years'
|
|
Jun 18
|
New Weight-Loss Drugs and Devices Are Coming This Week
|
|
Jun 18
|
Britain’s biggest stock broker poised to approve £5.4bn Abu Dhabi-backed takeover
|
|
Jun 18
|
Blaze at Danish drugmaker Novo Nordisk is the third in a little over a month
|
|
Jun 18
|
Brokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet
|
|
Jun 18
|
Novo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease at the 84th Scientific Sessions of the American Diabetes Association
|
|
Jun 17
|
Top Weight-Loss Rivals Share This Risk After Eye-Popping Runs
|
|
Jun 17
|
Could Structure Therapeutics Become the Next Novo Nordisk?
|